Eventide Asset Management LLC Raises Stake in Guardant Health, Inc. (NASDAQ:GH)

Eventide Asset Management LLC grew its stake in shares of Guardant Health, Inc. (NASDAQ:GH) by 2.0% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,837,300 shares of the company’s stock after buying an additional 76,762 shares during the quarter. Guardant Health accounts for approximately 1.5% of Eventide Asset Management LLC’s portfolio, making the stock its 14th largest holding. Eventide Asset Management LLC owned about 3.11% of Guardant Health worth $88,028,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of GH. JNBA Financial Advisors purchased a new position in shares of Guardant Health during the third quarter valued at approximately $26,000. Ashton Thomas Securities LLC purchased a new position in Guardant Health during the 3rd quarter valued at $34,000. Quarry LP bought a new position in Guardant Health in the 2nd quarter worth $44,000. Canton Hathaway LLC purchased a new stake in shares of Guardant Health in the 2nd quarter worth about $59,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Guardant Health during the 2nd quarter valued at about $71,000. 92.60% of the stock is currently owned by institutional investors.

Insider Activity

In related news, Director Meghan V. Joyce sold 2,896 shares of the stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $29.90, for a total value of $86,590.40. Following the completion of the transaction, the director now owns 7,648 shares of the company’s stock, valued at approximately $228,675.20. This trade represents a 27.47 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 5.50% of the company’s stock.

Guardant Health Trading Up 2.1 %

Shares of Guardant Health stock opened at $35.10 on Friday. Guardant Health, Inc. has a 1-year low of $15.81 and a 1-year high of $37.04. The company’s fifty day simple moving average is $25.00 and its 200-day simple moving average is $27.26. The company has a debt-to-equity ratio of 16.70, a current ratio of 6.22 and a quick ratio of 5.85. The stock has a market capitalization of $4.34 billion, a PE ratio of -8.28 and a beta of 1.11.

Guardant Health (NASDAQ:GH) last released its earnings results on Wednesday, November 6th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.33). The firm had revenue of $191.48 million during the quarter, compared to analysts’ expectations of $170.49 million. Guardant Health had a negative return on equity of 1,200.44% and a negative net margin of 74.02%. During the same period in the prior year, the company posted ($0.73) earnings per share. The company’s revenue was up 33.9% compared to the same quarter last year. As a group, equities analysts anticipate that Guardant Health, Inc. will post -3.38 earnings per share for the current year.

Wall Street Analyst Weigh In

GH has been the subject of a number of research reports. Citigroup increased their price target on shares of Guardant Health from $40.00 to $45.00 and gave the stock a “buy” rating in a research note on Thursday, August 8th. Sanford C. Bernstein lowered their target price on Guardant Health from $40.00 to $35.00 and set an “outperform” rating for the company in a research note on Wednesday, October 30th. The Goldman Sachs Group upped their price target on Guardant Health from $32.00 to $36.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. JPMorgan Chase & Co. increased their price objective on Guardant Health from $48.00 to $50.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Finally, TD Cowen boosted their target price on shares of Guardant Health from $41.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, August 8th. One research analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $40.60.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.